VC Built
for Builders,
by Builders
Using a technology-first approach, OMX takes groundbreaking discoveries and grows them into scalable biotech companies on both sides of the Atlantic.
Investing in Tomorrow’s Transformative Companies
We are at the beginning of biology revolutionizing our lives. This is enabled by data from novel Bio-Tools, Data, and Artificial Intelligence creating major new insights in biology. These insights will create the next generation of medicines, tools and solutions.
Portfolio Highlights
Delix is developing a class of novel non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles for the treatment of psychiatric and neurological indications.
Sector:
Therapeutics
Status:
Active
Freya is revolutionizing women's health through restoration of healthy vaginal microbiomes. Freya's first centers around improving the efficacy of in-vitro fertilization.
Sector:
Therapeutics
Status:
Active
Constructive Bio is pioneering approaches for building entirely synthetic genomes & for reprogramming the genetic code of living organisms for programmable polymer synthesis. Constructive Bio platform technologies have created virus resistant organisms, and are turning living cells into sustainable bio factories to realize the sustainable materials and therapies of the future.
Sector:
Synthetic Bio
Status:
Active
Matterworks is building a machine-learning software platform to enable users of mass spectrometry (MS) instruments to avoid chromatography steps in analyzing metabolomics samples, thereby achieving faster MS performance and covering a significantly broader range of analytes per run.
Sector:
BioTools & Diagnostics
Status:
Active
VedaBio is revolutionizing molecular biology with its breakthrough platform for near-instant molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. The CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries.
Sector:
BioTools & Diagnostics
Status:
Active
Glyphic Biotechnologies is building a next-generation proteomics platform with the depth of a single amino acid sequence and breadth to achieve this over thousand to million heterogeneous peptides. Furthermore, their platform is the only platform that combines both depth and breadth to detect post-translational modifications.
Sector:
BioTools & Diagnostics
Status:
Active
